Johnson & Johnson (NYSE:JNJ) said today that it plans to shut down its 410-worker Animas insulin pump subsidiary, offering to help some 90,000 Animas patients transfer to products made by rival Medtronic (NYSE:MDT).

The Chesterbrook, Pa.-based company said it will stop making its Animas Vibe and OneTouch Ping pumps, but will continue to provide customer service, training and warranty support during the transition to Medtronic pumps. Sales of the Animas pumps in the U.S. and Canada have already halted, with decision on markets outside the U.S. subject to talks with local authorities, the company said.

Get the full story at our sister site, Drug Delivery Business News.